Geron (GERN) Other Accumulated Expenses (2011 - 2024)
Geron (GERN) posted Other Accumulated Expenses of $2.1 million for Q4 2024, down 34.29% sequentially from $3.2 million in Q3 2024, and up 155.65% YoY from $814000.0 in Q1 2024.
Geron (GERN) Other Accumulated Expenses (2011 - 2024) Analysis & Trends
Geron has reported Other Accumulated Expenses for 14 years, with the latest figure at $2.1 million in Q4 2024.
- Quarterly Other Accumulated Expenses rose 155.65% year-over-year to $2.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.1 million (up 155.65% YoY) and the FY2024 annual result came in at $2.1 million, up 155.65% from the prior year.
- Other Accumulated Expenses declined to $2.1 million in Q4 2024 per GERN's latest filing, from $3.2 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $3.2 million in Q3 2024 and troughed at $366000.0 in Q2 2022.
- A 5-year average of $1.3 million and a median of $1.2 million in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses surged 452.19% in 2023, then dropped 16.72% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $388000.0 in 2020, then surged by 39.43% to $541000.0 in 2021, then declined by 5.73% to $510000.0 in 2022, then soared by 59.61% to $814000.0 in 2023, then jumped by 155.65% to $2.1 million in 2024.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.1 million, $3.2 million, and $1.7 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.08 Mn |
| Sep 30, 2024 | 3.17 Mn |
| Jun 30, 2024 | 1.68 Mn |
| Mar 31, 2024 | 1.65 Mn |
| Dec 31, 2023 | 814,000.00 |
| Sep 30, 2023 | 2.21 Mn |
| Jun 30, 2023 | 2.02 Mn |
| Mar 31, 2023 | 1.66 Mn |
| Dec 31, 2022 | 510,000.00 |
| Sep 30, 2022 | 664,000.00 |
| Jun 30, 2022 | 366,000.00 |
| Mar 31, 2022 | 555,000.00 |
| Dec 31, 2021 | 541,000.00 |
| Dec 31, 2020 | 388,000.00 |
| Dec 31, 2019 | 207,000.00 |
| Dec 31, 2018 | 461,000.00 |
| Sep 30, 2018 | 884,000.00 |
| Jun 30, 2018 | 724,000.00 |
| Mar 31, 2018 | 942,000.00 |
| Dec 31, 2017 | 138,000.00 |